Thus, it is important to underline that although ALT levels still represent the most used laboratory parameter to screen for NAFLD in routine clinical practice, they cannot be considered an optimal marker to predict NASH and advanced fibrosis, showing poor sensitivity in early NAFLD diagnosis and prognosis [49]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.